Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
≥18 years of age;
Diffuse large B-cell lymphoma diagnosed by pathological diagnosis according to WHO 2016 classification criteria;
Molecular subtyping, determined through high-throughput sequencing of pathological tissue or peripheral blood, is categorized as the "Other" subtype;
Immunohistochemistry revealed overexpression of MYC and BCL2: MYC ≥ 40%, BCL2 ≥ 50%;
Patients who meet any of the following criteria will be excluded from the study：
Currently enrolled in another clinical trial；
Received prior lymphoma treatment with alternative regimens before enrollment;
Presence of concurrent malignant tumors;
The First Affiliated Hospital with Nanjing Medical University
Lead sponsor